Clinical trials: Crohn's
Crohn Disease
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03467958
- Testing
- Ozanimod
- Where
- 766 sites in United States, Argentina and 47 more
- Volunteers
- 854 people
- Sponsor
- Celgene
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Perianal Fistula Due to Crohn's Disease
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing…
- Trial name
- NCT06918808
- Testing
- DB-3Q
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Colitis Ulcerative, Crohn's Disease
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week…
- Trial name
- NCT07222189
- Testing
- balinatunfib
- Where
- 10 sites in United States, Argentina and 5 more
- Volunteers
- 7 people
- Sponsor
- Sanofi
Crohn's Disease
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
The primary objective is to evaluate digestive damage in CD 5 to 10 years after diagnosis in the GETAID centers included in the RAPID study. Secondary objective is to identify predictive factors of the evolution digestive damage.
- Trial name
- DESTIN (NCT02549976)
- Testing
- Abdominal MRI, Upper endoscopy, Colonoscopy
- Where
- 9 sites in France
- Volunteers
- 54 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn Disease (CD), Postoperative Recurrence and Metastasis
Prediction of Postoperative Recurrence in Crohn's Disease
This multicenter prospective observational cohort study aims to develop and validate a multimodal prediction model for postoperative recurrence in patients with Crohn's disease.
- Trial name
- NCT07824791
- Testing
- Intestinal Resection, Biospecimen Collection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pediatric Crohn's Disease
Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease
Crohn's disease (CD) is an incurable debilitating disorder affecting an increasing number of children. The etiology remains elusive, but a genetically determined aberrant immune response against microbiota appears to be…
- Trial name
- NCT01752790
- Testing
- Top-down, Step-up
- Where
- Italy
- Sponsor
- University of Roma La Sapienza
Crohn Disease
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
- Trial name
- NCT00206713
- Testing
- Sargramostim (Leukine)
- Where
- 7 sites in United States
- Volunteers
- 264 people
- Sponsor
- Genzyme, a Sanofi Company
Crohn's Disease
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
A 26 week maintenance study of CDP870 in Crohn's disease
- Trial name
- NCT00152425
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 392 people
- Sponsor
- UCB Pharma
Irritable Bowel Syndrome (IBS)
IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome
Background: Irritable Bowel Syndrome (IBS) affects approximately 4.1% of the global population and imposes a significant personal and healthcare burden.
- Trial name
- IBS-CDED (NCT07707635)
- Testing
- Modified Crohn's Disease Exclusion Diet (CDED), Low FODMAP Diet
- Volunteers
- 150 people
- Sponsor
- Ariel University
Crohn Disease (CD), Cryptoglandular Perianal Fistula
A Study Comparing Transperineal Ultrasound, Magnetic Resonance Imaging, Endoscopic Ultrasound, and Examination Under Anesthesia to Detect and Classify Perianal Fistulas in Patients With Crohn's Disease or Fistulas of Unknown Cause
The goal of this study is to learn how well different imaging tests detect and describe perianal fistulas in adults with Crohn's disease or fistulas with no known cause (cryptogenic).
- Trial name
- TRANSIT CD (NCT07794410)
- Testing
- Transperineal Ultrasound (TPUS), Magnetic Resonance Imaging (MRI), Endoscopic Ultrasound (EUS)
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn Disease
The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )
The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children diagnosed Crohn's disease…
- Trial name
- ViDiPeC-2 (NCT03999580)
- Testing
- vitamin D3
- Where
- 7 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Jantchou Prevost
Crohn Disease
Triple Combination Therapy in High Risk Crohn's Disease (CD)
The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an…
- Trial name
- NCT02764762
- Testing
- Vedolizumab, Adalimumab, Methotrexate
- Where
- 32 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Takeda
Crohn's Disease, Inflammatory Bowel Disease
A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.
This randomized placebo-controlled double-blind, multi-centre trial will determine the efficacy of the probiotic VSL#3 in the prevention of Crohn's disease development following surgical resection and re-anastomosis.
- Trial name
- NCT00175292
- Testing
- Probiotic - VSL#3
- Where
- 17 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University of Alberta
Healthy First Degree Relatives of Crohn's Disease Patients
Prebiotics and Diet to Reduce "Leaky" Gut in First Degree Relatives of Crohn's Disease Patients
Crohn's disease (CD) is a recurring inflammation of the intestines. The etiology is unknown; however evidence suggests that it could be a combination of gut microbes, environmental factors and genetics.
- Trial name
- NCT03950336
- Testing
- Prebiotics, Low n-6 PUFA Diet, Maltodextrin
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- University of Alberta
Crohns Disease
Oral N-acetylglucosamine in Crohn's Disease
Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of physiological processes.
- Trial name
- NAGIC (NCT07225998)
- Testing
- N-Acetylglucosamine (GlcNAc)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Fibrostenotic Crohn's Disease
A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical…
- Trial name
- NCT07118878
- Testing
- AGMB-129
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Agomab Spain S.L.U.
Crohn's Disease
Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study
Nearly three-quarters of patients with Crohn's disease have small bowel involvement and 80% of them will have complications that will require a surgical procedure, usually an ileocolonic resection with ileocolonic anastomosis.
- Trial name
- MRI-CROHN (NCT02867540)
- Testing
- MRI enterography
- Where
- France
- Volunteers
- 40 people
- Sponsor
- CHU de Reims
Crohn's Disease
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks.
- Trial name
- CD05 (NCT00740103)
- Testing
- Semapimod
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 119 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease
Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease
Recent data suggest that diet in inflammatory bowel disease (IBD) may lead to both symptom control and disease remission. Historically certain diets have been recommended for patients with Crohn's disease during exacerbations…
- Trial name
- NCT03012542
- Testing
- Diet 1, Diet 2
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington